Italy's National Health Service is developing an evidence-based framework to incorporate healthspan—years lived with preserved function—as a measurable outcome alongside life expectancy. The proposal outlines a staged adoption pathway for aging biomarkers, digital monitoring, and preventive interventions, requiring clinical utility and cost-effectiveness validation before implementation in routine care.
Key Points
- Italy's lifespan-healthspan gap reaches 15.8 years for women, 12.9 for men
- Framework prioritizes validation before adopting aging clocks, AI risk tools, geroprotective drugs
- Five priorities: biomarker standardization, interoperable digital platforms, adaptive trials, explai
Longevity Analysis
This framework addresses a fundamental gap in public health measurement: the distinction between living longer and living well. By shifting from reactive disease management to prospective functional assessment, the SSN would reorient toward detecting unfavorable aging trajectories earlier—when intervention can still meaningfully preserve autonomy. The staged approach is noteworthy because it refuses premature adoption of unvalidated biomarkers or pharmaceutical interventions, instead requiring evidence of patient-relevant outcomes before systemic integration. For practitioners, this signals the convergence of geroscience into health-system operations: digital platforms tracking function, prevention weighted as heavily as treatment in reimbursement, and deprescribing recognized as a core clinical skill. The emphasis on regional interoperability and socioeconomic equity acknowledges that aging trajectories are shaped by modifiable environmental and behavioral factors—not genetics or agin
Original published by Longevity.Technology, by Guest Contributor.